NCT00820248 - Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer | Biotech Hunter

Enrollment

320

Participants

Timeline

Start Date

December 30, 2008

Primary Completion Date

May 16, 2015

Study Completion Date

February 17, 2017

Conditions

Head and Neck Cancer

Interventions

BIOLOGICAL

panitumumab

Given IV

DRUG

cisplatin

Given IV

RADIATION

3-dimensional conformal radiation therapy

Patients undergo radiotherapy

RADIATION

accelerated radiation therapy

Patients undergo accelerated fractionation radiotherapy

RADIATION

intensity-modulated radiation therapy

Patients undergo radiotherapy

Trial Locations (19)

T6G 1Z2

Cross Cancer Institute, Edmonton

V3V 1Z2

BCCA - Fraser Valley Cancer Centre, Surrey

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

E2L 4L2

Atlantic Health Sciences Corporation, Saint John

AIB 3V6

Dr. H. Bliss Murphy Cancer Centre, St. John's

P3E 5J1

Northeast Cancer Center Health Sciences, Greater Sudbury

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston, Kingston

N6A 4L6

London Regional Cancer Program, London

K1H 8L6

Ottawa Health Research Institute - General Division, Ottawa

P7B 6V4

Thunder Bay Regional Health Science Centre, Thunder Bay

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

H1T 2M4

Hopital Maisonneuve-Rosemont, Montreal

H2W 1S6

McGill University - Dept. Oncology, Montreal

G1R 2J6

CHUQ-Pavillon Hotel-Dieu de Quebec, Québec

J1H 5N4

Centre hospitalier universitaire de Sherbrooke, Sherbrooke

S4T 7T1

Allan Blair Cancer Centre, Regina

S7N 4H4

Saskatoon Cancer Centre, Saskatoon